Free Trial
NASDAQ:ALDX

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Aldeyra Therapeutics logo
$4.65 -0.15 (-3.13%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.70 +0.05 (+1.08%)
As of 07/11/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

Key Stats

Today's Range
$4.55
$4.81
50-Day Range
$2.01
$4.80
52-Week Range
$1.14
$7.20
Volume
1.38 million shs
Average Volume
875,528 shs
Market Capitalization
$278.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
Consensus Rating
Buy

Company Overview

Aldeyra Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

ALDX MarketRank™: 

Aldeyra Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 501st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Aldeyra Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aldeyra Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aldeyra Therapeutics is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aldeyra Therapeutics has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Aldeyra Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.26% of the float of Aldeyra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aldeyra Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aldeyra Therapeutics has recently decreased by 0.45%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aldeyra Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aldeyra Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.26% of the float of Aldeyra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aldeyra Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aldeyra Therapeutics has recently decreased by 0.45%, indicating that investor sentiment is improving.
  • News Sentiment

    Aldeyra Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Aldeyra Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    8 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of Aldeyra Therapeutics is held by insiders.

  • Percentage Held by Institutions

    59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aldeyra Therapeutics' insider trading history.
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALDX Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Aldeyra Therapeutics Inc.
See More Headlines

ALDX Stock Analysis - Frequently Asked Questions

Aldeyra Therapeutics' stock was trading at $4.99 at the beginning of the year. Since then, ALDX shares have decreased by 6.8% and is now trading at $4.65.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) released its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.08.

Aldeyra Therapeutics' top institutional investors include Woodstock Corp (0.45%), Wealth Enhancement Advisory Services LLC (0.05%), Pallas Capital Advisors LLC (0.03%) and Inspirion Wealth Advisors LLC (0.02%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Bruce Greenberg and Nancy Miller-Rich.
View institutional ownership trends
.

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX).

Company Calendar

Last Earnings
5/14/2025
Today
7/12/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALDX
CIK
1341235
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$9.00
Potential Upside/Downside
+104.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-72.58%
Return on Assets
-52.32%

Debt

Debt-to-Equity Ratio
0.24
Current Ratio
6.49
Quick Ratio
6.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.19 per share
Price / Book
3.91

Miscellaneous

Outstanding Shares
59,900,000
Free Float
54,146,000
Market Cap
$278.54 million
Optionable
Optionable
Beta
0.90

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ALDX) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners